Results from two pivotal Phase 3 trials for secukinumab (Cosentyx) in plaque psoriasis were published on 2014-01-01. These trials, including the ERASURE study, investigated the efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis.
Background
Secukinumab (Cosentyx) was investigated for the treatment of moderate to severe chronic plaque-type psoriasis. Plaque psoriasis is a chronic autoimmune condition affecting the skin.
Trial design
Two Phase 3 trials, including the ERASURE study, evaluated secukinumab for moderate to severe chronic plaque-type psoriasis. The ERASURE study specifically focused on the efficacy and safety of subcutaneous secukinumab for this condition over a period of up to 1 year.
What this means
The publication of results from two pivotal Phase 3 trials for secukinumab (Cosentyx) marks a significant step in the development of treatments for moderate to severe chronic plaque-type psoriasis. While specific efficacy and safety data are not detailed here, the focus of these trials, including the ERASURE study, was to establish the drug's profile for this challenging condition. Clinicians and researchers can refer to the full publication for detailed findings on secukinumab's performance.
Source
The information regarding these trial results was sourced from PubMed, a database of biomedical literature. The publication, titled "Secukinumab in plaque psoriasis--results of two phase 3 trials," was made available on 2014-01-01, with the abstract accessible via pubmed.ncbi.nlm.nih.gov.